Health Technology Assessment

All Items

• Patient-reported outcomes in epilepsy: a case study exploring their usage and impact

  Simona Lattanzi, Angela La Neve

  108-114

  DOI: https://doi.org/10.33393/grhta.2024.3020

• Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy

  Andrea Messori, Maria Rita Romeo, Valeria Fadda, Francesca Collini, Sabrina Trippoli

  105-107

  DOI: https://doi.org/10.33393/grhta.2024.3018

• Heart failure and economic impact: an analysis in real clinical practice in Italy

  Melania Dovizio, Melania Leogrande, Luca Degli Esposti

  94-100

  DOI: https://doi.org/10.33393/grhta.2024.3013

• The socioeconomic burden of adult attention-deficit/hyperactivity disorder in Spain

  Maria Merino, Paulina Maravilla-Herrera, Teresa Martín Lorenzo, Juan Antonio Arance, Julio Bobes, Montse Corrales, Fátima Guzmán, María Morales, Carlos Mur

  82-93

  DOI: https://doi.org/10.33393/grhta.2024.2697

• The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example

  Mickaël Hiligsmann, Olivier Bruyère

  75-81

  DOI: https://doi.org/10.33393/grhta.2024.2682

• Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis

  Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio

  55-67

  DOI: https://doi.org/10.33393/grhta.2024.2658

• Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy

  Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio

  38-50

  DOI: https://doi.org/10.33393/grhta.2024.2728

• Clinical and economic burden of peristomal skin complications: Activity Based Costing analysis

  Agostino Fortunato, Filippo Rumi, Massimo Zazzetta, Marco Della Valle, Vincenzo Pedace, Americo Cicchetti

  31-37

  DOI: https://doi.org/10.33393/grhta.2024.2639

• A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

  Michele Basile, Ilaria Valentini, Roberto Attanasio, Renato Cozzi, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Renata Simona Auriemma, Ernesto De Menis, Felice Esposito, Emanuele Ferrante, Giuseppe Iatì, Diego Mazzatenta, Maurizio Poggi, Roberta Rudà, Fabio Tortora, Fabio Cruciani, Zuzana Mitrova, Rosella Saulle, Simona Vecchi, Paolo Cappabianca, Agostino Paoletta, Alessandro Bozzao, Marco Caputo, Francesco Doglietto, Francesco Ferraù, Andrea Gerardo Lania, Stefano Laureti, Stefano Lello, Davide Locatelli, Pietro Maffei, Giuseppe Minniti, Alessandro Peri, Chiara Ruini, Fabio Settanni, Antonio Silvani, Nadia Veronese, Franco Grimaldi, Enrico Papini, Americo Cicchetti

  1-16

  DOI: https://doi.org/10.33393/grhta.2024.2601

• Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

  Alison Davie, Sory Traoré, Massimo Giovannitti, Giuseppe Pompilio, Mark Lambton, Esra Cakar, Anuja Chatterjee

  62-69

  DOI: https://doi.org/10.33393/grhta.2023.2561

• Good practices for the development of budget impact models at regional level

  Andrea Marcellusi, Angela Ragonese, Andrea Marinozzi, Alberto Bortolami, Sara Mucherino, Carolina Moreno, Amalia Antenori, Matteo Ferrario, Claudia Simonelli, Matteo Zanuzzi, Marco Cicoira, Ruggero Lasala, Francesco Russoniello, Francesco Attanasio, Caterina Donati, Chiara Roni, Fabrizio Gemmi, Francesco Saverio Mennini, Pierluigi Russo, Giovanna Scroccaro, PierLuigi Canonico

  53-61

  DOI: https://doi.org/10.33393/grhta.2023.2582

• COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment

  Beatrice Canali, Laura Candelora, Francesca Fiorentino, Tom Halmos, Paola La Malfa, Francesca Massara, Chiara Vassallo, Duccio Urbinati

  46-52

  DOI: https://doi.org/10.33393/grhta.2023.2560

• Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infections

  Martina Paoletti, Andrea Marcellusi, Joe Yang, Francesco Saverio Mennini

  18-28

  DOI: https://doi.org/10.33393/grhta.2023.2488

• Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy

  Francesca Fiorentino, Paolo Di Rienzo

  29-39

  DOI: https://doi.org/10.33393/grhta.2023.2507

• Budget Impact analysis of a new system of care in Parkinson’s disease patients

  Chiara Bini, Francesco Saverio Mennini, Andrea Marcellusi, Martina Paoletti, Carlo Tomino

  91-98

  DOI: https://doi.org/10.33393/grhta.2022.2413

• Disability weights for castration-resistant prostate cancer: an empirical investigation

  Ludovica Borsoi, Oriana Ciani, Rocco De Vivo, Giorgio Ivan Russo, Marcello Scarcia, Chiara De Fino, Patrizia Beccaglia, Irene Luccarini

  146-154

  DOI: https://doi.org/10.33393/grhta.2022.2431

• Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy

  Giuseppe Pompilio, Davide Integlia

  138-145

  DOI: https://doi.org/10.33393/grhta.2022.2474

• Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain

  Prof. Dr. Jaime Rodríguez Quintosa, Dr. Cintia Cristina Ago, Dr. Antoni Sicras Mainar, Dr. Renata Villoro, Dr. Inés Pérez-Román

  133-137

  DOI: https://doi.org/10.33393/grhta.2022.2439

• Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis

  Gian Domenico Sebastiani, Marta Mosca, Roberto Ravasio, Pietro Brambilla, Paola Raimondo, Andrea Doria

  123-132

  DOI: https://doi.org/10.33393/grhta.2022.2470

• Economic evaluation of treosulfan in patients undergoing allogeneic haematopoietic stem cell transplantation

  Chiara Bini, Martina Paoletti, Andrea Marcellusi, Carlo Tomino, Francesco Saverio Mennini

  105-116

  DOI: https://doi.org/10.33393/grhta.2022.2412

• Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

  Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo

  82-90

  DOI: https://doi.org/10.33393/grhta.2022.2449

• The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

  Arianna Bertolani, Roberto Ravasio, Paola Raimondo, Claudio Jommi

  73-81

  DOI: https://doi.org/10.33393/grhta.2022.2415

• Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis

  Filippo Rumi, Michele Basile, Americo Cicchetti, Rosario Contiguglia, Antonella Pentassuglia, Alessandro Oliva, Gianenrico Senna, Marco Bonavia, Francesco Scarpelli, Marco Benvenuto

  58-67

  DOI: https://doi.org/10.33393/grhta.2022.2290

• Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)

  Francesco Saverio Mennini, Martina Paoletti, Chiara Bini, Andrea Marcellusi, Marco Falcone, Massimo Andreoni

  45-57

  DOI: https://doi.org/10.33393/grhta.2022.2287

• Distribution methods of ostomy and incontinence aids in the Italian healthcare setting: an evaluation questionnaire and social burden of direct distribution

  Filippo Rumi, Francesca Orsini, Vincenzo Falabella, Pier Raffaele Spena, Americo Cicchetti

  36-44

  DOI: https://doi.org/10.33393/grhta.2022.2292